Amikacin Adult Dosing
For adults with normal renal function, administer amikacin 15 mg/kg/day (maximum 1.0 g/day) intramuscularly or intravenously as a single daily dose, with dose reduction to 10 mg/kg/day (750 mg) for patients over 59 years of age. 1
Standard Dosing Regimens
Normal Renal Function
- Initial dosing: 15 mg/kg/day IM or IV, divided as either:
- 7.5 mg/kg every 12 hours, OR
- 5 mg/kg every 8 hours 1
- Maximum daily dose: 1.5 g/day (do not exceed 15 mg/kg/day total) 1
- Age adjustment: Reduce to 10 mg/kg/day (750 mg maximum) for patients >59 years 2, 3
Alternative Dosing for Specific Indications
For non-tuberculous mycobacterial (NTM) infections, more aggressive dosing may be warranted:
- Daily dosing: 15 mg/kg once daily or 7.5 mg/kg twice daily
- Intermittent dosing: 15-25 mg/kg three times weekly 4
- For cystic fibrosis patients with NTM: 10-30 mg/kg once daily or 15 mg/kg/day in two divided doses, with flexibility for daily to 3× weekly dosing 5
For drug-resistant tuberculosis, the regimen follows a phased approach:
- Initial phase: 15 mg/kg/day (maximum 1.0 g) as single daily dose, 5-7 days/week
- Continuation phase: Reduce to 2-3 times weekly after first 2-4 months or after culture conversion 2, 3
Renal Impairment Adjustments
Critical principle: In renal insufficiency, maintain the milligram dose at 12-15 mg/kg but reduce dosing frequency to preserve concentration-dependent bactericidal activity. 2, 3
Dosing Interval Extension Method
- Calculate dosing interval (hours) = serum creatinine (mg/dL) × 9
- Example: If serum creatinine = 2 mg/dL, give 7.5 mg/kg every 18 hours 1
Dose Reduction Method
For patients requiring fixed intervals with renal impairment:
- Give loading dose of 7.5 mg/kg
- Calculate maintenance dose:
- Maintenance dose = (observed CrCl / normal CrCl) × calculated loading dose
- Administer every 12 hours 1
Alternative simplified approach: Divide normally recommended dose by patient's serum creatinine value 1
Hemodialysis Patients
- Maintain dose at 12-15 mg/kg per dose
- Reduce frequency to 2-3 times weekly
- Administer after dialysis to facilitate directly observed therapy and avoid premature drug removal 2, 3
Intravenous Administration
- Dilute 500 mg vial in 100-200 mL of sterile diluent (0.9% NaCl or 5% dextrose)
- Infusion duration:
- Total daily dose identical to IM dosing 1
Therapeutic Drug Monitoring
Mandatory monitoring parameters to minimize nephrotoxicity and ototoxicity:
Target Concentrations
- Peak (Cmax):
- Trough:
Monitoring Schedule
- Peak levels: First week, repeat if poor response 4
- Trough levels: Weekly for 4 weeks, then fortnightly when stable 4
- Renal function: Twice weekly during month 1, weekly during month 2, then fortnightly 4
- Auditory/vestibular: Baseline audiogram, vestibular testing, Romberg testing; monthly assessments with symptom questioning; repeat if eighth nerve toxicity symptoms develop 2, 3
Critical Safety Considerations
Nephrotoxicity Risk Factors
- Renal impairment was observed in 8.7% of patients receiving amikacin, with higher frequency in those with:
- Amikacin is more nephrotoxic than streptomycin 2, 3, 2
Ototoxicity Risk Factors
- High-frequency hearing loss occurred in 24% in one report, though literature review found only 1.5% 2, 3, 2
- Causes primarily deafness with less vestibular dysfunction than streptomycin 2, 3, 2
- Risk increased with:
Absolute Contraindications
Treatment Duration
- Usual duration: 7-10 days 1
- If treatment extends beyond 10 days: Re-evaluate necessity and monitor serum levels, renal function, auditory and vestibular function closely 1
Special Populations
Obesity
For markedly obese patients, calculate adjusted dose using:
- Adjusted body weight = ideal body weight + 0.4 × (actual weight - ideal body weight)
- Male IBW (kg) = 50 + (2.3 × height in cm above 152.4)/2.54
- Female IBW (kg) = 45.5 + (2.3 × height in cm above 152.4)/2.54 4
Uncomplicated UTI
- Alternative regimen: 250 mg twice daily 1
Common Pitfalls to Avoid
- Do NOT reduce the milligram dose in renal impairment—only extend the interval to maintain concentration-dependent killing 2, 3
- Do NOT physically premix amikacin with other drugs—administer separately 1
- Do NOT use fixed dosing without weight-based calculation—toxicity risk increases 1
- Do NOT continue beyond 10 days without reassessment and intensified monitoring 1
- Do NOT forget age-based dose reduction for patients >59 years 2, 3